Catalent, Inc. (NYSE:CTLT) Stake Lifted by Alpine Associates Management Inc.

Alpine Associates Management Inc. raised its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 3.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,061,251 shares of the company's stock after purchasing an additional 75,700 shares during the quarter. Catalent comprises 5.5% of Alpine Associates Management Inc.'s investment portfolio, making the stock its 5th biggest position. Alpine Associates Management Inc. owned 1.14% of Catalent worth $115,904,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in CTLT. Norges Bank acquired a new stake in shares of Catalent in the fourth quarter valued at $116,021,000. Capital World Investors grew its position in Catalent by 6.1% in the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company's stock valued at $857,264,000 after acquiring an additional 1,098,474 shares in the last quarter. Magnetar Financial LLC purchased a new stake in Catalent during the first quarter worth about $56,429,000. Cadian Capital Management LP lifted its position in shares of Catalent by 14.3% during the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company's stock worth $272,473,000 after purchasing an additional 759,600 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Catalent by 2,792.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company's stock valued at $29,150,000 after purchasing an additional 498,540 shares during the period.

Catalent Stock Up 0.9 %

Shares of CTLT stock traded up $0.54 on Monday, reaching $60.16. 990,244 shares of the stock were exchanged, compared to its average volume of 2,099,990. The company has a market capitalization of $10.92 billion, a price-to-earnings ratio of -9.77, a PEG ratio of 1.88 and a beta of 1.15. The business's 50 day moving average price is $59.21 and its 200 day moving average price is $57.11. The company has a current ratio of 2.52, a quick ratio of 1.77 and a debt-to-equity ratio of 1.35. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $61.20.

Insider Transactions at Catalent

In related news, SVP Scott Gunther sold 666 shares of the company's stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares of the company's stock, valued at $2,360,264.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the firm's stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares of the company's stock, valued at $10,431,133.96. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Scott Gunther sold 666 shares of the business's stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the sale, the senior vice president now directly owns 39,635 shares of the company's stock, valued at $2,360,264.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,409 shares of company stock valued at $782,923. 0.31% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CTLT shares. Royal Bank of Canada reiterated a "sector perform" rating and set a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. StockNews.com initiated coverage on Catalent in a report on Tuesday, September 10th. They issued a "sell" rating for the company. Barclays boosted their target price on Catalent from $47.00 to $63.00 and gave the stock an "equal weight" rating in a research note on Friday, June 28th. Finally, William Blair reaffirmed a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $58.08.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.